Nitric oxide - ProStrakan
Alternative Names: S-291-N; TNO therapy - ProStrakan; Topical nitric oxide - ProStrakanLatest Information Update: 02 Oct 2021
At a glance
- Originator ProStrakan
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Human papillomavirus infections; Molluscum contagiosum; Onychomycosis
Most Recent Events
- 08 Sep 2005 This compound is still in active development for Onychomycosis
- 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
- 21 Jun 2004 Phase-II clinical trials in Human papillomavirus infections in United Kingdom (Topical)